DOCSLIB.ORG

Bronchitis, Acute

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bronchitis, Acute BRONCHITIS, ACUTE BASIC INFORMATION DESCRIPTION • Treatment is directed toward relieving the symptoms, Inflammation of the air passages (trachea; bronchi; unless there are signs of secondary bacterial infection: bronchioles) of the lungs. Acute bronchitis is of sudden green sputum, fever over 101° F or worsening symptoms. onset and short duration (chronic bronchitis is persistent • If you are a smoker, don’t smoke during your illness. over a long period and recurring over several This delays recovery and makes complications more years). likely. FREQUENT SIGNS AND SYMPTOMS • Increase air moisture. Take frequent hot showers. Use • Cough that produces little or no sputum initially, but a cool-mist, ultrasonic humidifier by your bed. Clean does later on. humidifier daily. • Low fever (usually less than 101° F or 38.3° C). • Additional information available from the American • Burning chest discomfort or feeling of pressure Lung Association, 1740 Broadway, New York, NY behind the breastbone. 10019, (800) 586-4872. • Wheezing or uncomfortable breathing (sometimes). MEDICATIONS CAUSES • For minor discomfort, you may use: • Infection from one of many respiratory viruses. Most Acetaminophen to reduce fever. cases of acute bronchitis begin with a cold virus in the Non-prescription cough suppressants. Use only if nose and throat that spreads to the airways. A secondary your cough is non-productive (without sputum). It may bacterial infection is common. be dangerous to stop a cough entirely as this traps • Lung inflammation from breathing air that contains excess mucus and irritants in bronchial tubes, leading to irritants, such as chemical fumes (ammonia), acid pneumonia and poor oxygen exchange in the lungs. fumes, dust or smoke. • Other drugs that may be prescribed: RISK INCREASES WITH Antibiotics to fight bacterial infections. • Chronic obstructive pulmonary disease (COPD). Expectorants to thin mucus so it can be coughed up • Smoking. more easily. • Cold, humid weather. Cough suppressants. • Poor nutrition. ACTIVITY • Recent illness that has lowered resistance. Rest in bed until temperature returns to normal. Then • Areas with high atmospheric pollution. resume normal activity gradually as symptoms improve. • Elderly and very young age groups. DIET PREVENTIVE MEASURES No special diet. Drink at least 8 to 10 glasses of fluid • Avoid close contact with persons who have bronchitis. each day to help thin mucus secretions so they can be • Don’t smoke. coughed up more easily. • If you work with chemicals, dust or other lung irritants, wear an appropriate face mask. NOTIFY OUR OFFICE IF EXPECTED OUTCOMES • You or a family member has symptoms of bronchitis. Usually curable with treatment in 1 week. Cases with • The following occur during the illness: complications are usually curable in 2 weeks with High fever and chills. medication. Chest pain. POSSIBLE COMPLICATIONS Thickened, discolored or blood-streaked sputum. • Bacterial lung infection (various kinds of pneumonia). Shortness of breath, even when the body is at rest. • Chronic bronchitis from recurrent episodes of acute Vomiting. bronchitis. • Cough may persist for several weeks after initial improvement. • Pleurisy (inflammation of the lining of the lungs) (rare). TREATMENT GENERAL MEASURES Adapted from Instructions for Patients, Sixth Edition, H. Winter • Diagnosis is usually based on the symptoms Griffith, M.D., W.B Saunders Company displayed, but a sputum culture may be done to check for bacterial infection. .
Load more

Recommended publications
  • Allergic Bronchopulmonary Aspergillosis Revealing Asthma
    CASE REPORT published: 22 June 2021 doi: 10.3389/fimmu.2021.695954 Case Report: Allergic Bronchopulmonary Aspergillosis Revealing Asthma Houda Snen 1,2*, Aicha Kallel 2,3*, Hana Blibech 1,2, Sana Jemel 2,3, Nozha Ben Salah 1,2, Sonia Marouen 3, Nadia Mehiri 1,2, Slah Belhaj 3, Bechir Louzir 1,2 and Kalthoum Kallel 2,3 1 Pulmonary Department, Hospital Mongi Slim, La Marsa, Tunisia, 2 Faculty of Medicine, Tunis El Manar University, Tunis, Tunisia, 3 Parasitology and Mycology Department, La Rabta Hospital, Tunis, Tunisia Allergic bronchopulmonary aspergillosis (ABPA) is an immunological pulmonary disorder caused by hypersensitivity to Aspergillus which colonizes the airways of patients with asthma and cystic fibrosis. Its diagnosis could be difficult in some cases due to atypical Edited by: presentations especially when there is no medical history of asthma. Treatment of ABPA is Brian Stephen Eley, frequently associated to side effects but cumulated drug toxicity due to different molecules University of Cape Town, South Africa is rarely reported. An accurate choice among the different available molecules and Reviewed by: effective on ABPA is crucial. We report a case of ABPA in a woman without a known Shivank Singh, Southern Medical University, China history of asthma. She presented an acute bronchitis with wheezing dyspnea leading to an Richard B. Moss, acute respiratory failure. She was hospitalized in the intensive care unit. The Stanford University, United States bronchoscopy revealed a complete obstruction of the left primary bronchus by a sticky *Correspondence: Houda Snen greenish material. The culture of this material isolated Aspergillus fumigatus and that of [email protected] bronchial aspiration fluid isolated Pseudomonas aeruginosa.
    [Show full text]
  • Symptoms Related to Asthma and Chronic Bronchitis in Three Areas of Sweden
    Eur Respir J, 1994, 7, 2146–2153 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07122146 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Symptoms related to asthma and chronic bronchitis in three areas of Sweden E. Björnsson*, P. Plaschke**, E. Norrman+, C. Janson*, B. Lundbäck+, A. Rosenhall+, N. Lindholm**, L. Rosenhall+, E. Berglund++, G. Boman* Symptoms related to asthma and chronic bronchitis in three areas of Sweden. E. Björnsson, *Dept of Lung Medicine and Asthma P. Plaschke, E. Norrman, C. Janson, B. Lundbäck, A. Rosenhall, N. Lindholm, L. Research Center, Akademiska sjukhu- Rosenhall, E. Berglund, G. Boman. ERS Journals Ltd 1994. set, Uppsala University, Uppsala, Sweden. ABSTRACT: Does the prevalence of respiratory symptoms differ between regions? **Asthma and Allergy Research Center, Sahlgren's Hospital, University of Göteborg, As a part of the European Community Respiratory Health Survey, we present data Göteborg, Sweden. +Dept of Pulmonary from an international questionnaire on asthma symptoms occurring during a 12 Medicine and Allergology, Univer- month period, smoking and symptoms of chronic bronchitis. The questionnaire was sity Hospital of Northern Sweden, Umeå, mailed to 10,800 persons aged 20–44 yrs living in three regions of Sweden (Västerbotten, Sweden. ++Dept of Pulmonary Medicine, Uppsala and Göteborg) with different environmental characteristics. The total Sahlgrenska University Hospital, Göteborg, response rate was 86%. Sweden. Wheezing was reported by 20.5%, and the combination of wheezing without a Correspondence: E. Björnsson, Dept of cold and wheezing with breathlessness by 7.4%. The use of asthma medication was Lung Medicine, Akademiska sjukhuset, S- reported by 5.3%.
    [Show full text]
  • Acute (Serious) Bronchitis
    Acute (serious) Bronchitis This is an infection of the air tubes that go down to your lungs. It often follows a cold or the flu. Most people do not need treatment for this. The infection normally goes away in 7-10 days. We make every effort to make sure the information is correct (right). However, we cannot be responsible for any actions as a result of using this information. Getting Acute Bronchitis How the lungs work Your lungs are like two large sponges filled with tubes. As you breathe in, you suck oxygen through your nose and mouth into a tube in your neck. Bacteria and viruses in the air can travel into your lungs. Normally, this does not cause a problem as your body kills the bacteria, or viruses. However, sometimes infection can get through. If you smoke or if you have had another illness, infections are more likely to get through. Acute Bronchitis Acute bronchitis is when the large airways (breathing tubes) to the lungs get inflamed (swollen and sore). The infection makes the airways swell and you get a build up of phlegm (thick mucus). Coughing is a way of getting the phlegm out of your airways. The cough can sometimes last for up to 3 weeks. Acute Bronchitis usually goes away on its own and does not need treatment. We make every effort to make sure the information is correct (right). However, we cannot be responsible for any actions as a result of using this information. Symptoms (feelings that show you may have the illness) Symptoms of Acute Bronchitis include: • A chesty cough • Coughing up mucus, which is usually yellow, or green • Breathlessness when doing more energetic activities • Wheeziness • Dry mouth • High temperature • Headache • Loss of appetite The cough usually lasts between 7-10 days.
    [Show full text]
  • Octreotide Treatment of Idiopathic Pulmonary Fibrosis: a Proof-Of-Concept Study
    drugs, while two patients underwent surgery in addition to Roncaccio 16, 21049, Tradate, Italy. E-mail: giovannibattista. chemotherapy. [email protected] As in other reference centres, the E. Morelli Hospital needs to transfer out all admitted cases to the hospitals referring them for Support Statement: This study was supported by the current specialised treatment, when culture conversion and clinical research funds of the participating institutions. For this stability have been achieved. Patients were transferred out after publication, the research leading to these results has received a median (IQR) hospital stay of 75.5 (51.5–127.5) days; 12 (100%) funding from the European Community’s Seventh Framework out of 12 and nine (75%) out of 12 achieved sputum-smear and Programme (FP7/2007-2013) under grant agreement FP7- culture conversion, after a median (IQR) time of 40.5 (24–64) and 223681. 70 (44–95) days, respectively. As of June 2011, one patient was cured, two had died and nine were still under treatment. Statement of Interest: None declared. Four (33.3%) cases reported adverse events, two being major (16.7%; neuropathy and low platelet count, needing temporary REFERENCES interruption of linezolid) and two minor (neuropathy and mild 1 Villar M, Sotgiu G, D’Ambrosio L, et al. Linezolid safety, anaemia). All adverse events were reversible. tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730–733. In conclusion, despite the intrinsic difficulty of evaluating the 2 World Health Organization. Multidrug and extensively drug safety and tolerability of linezolid (administered within different resistant TB (M/XDR-TB): 2010 global report on surveillance and regimens including multiple anti-TB drugs guided by drug response.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation
    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation Dr Rohit Bazaz National Aspergillosis Centre, UK Manchester University NHS Foundation Trust/University of Manchester ~ ABPA -a41'1 Severe asthma wl'th funga I Siens itisat i on Subacute IA Chronic pulmonary aspergillosjs Simp 1Ie a:spe rgmoma As r§i · bronchitis I ram une dysfu net Ion Lun· damage Immu11e hypce ractivitv Figure 1 In t@rarctfo n of Aspergillus Vliith host. ABP A, aHerg tc broncho pu~ mo na my as µe rgi ~fos lis; IA, i nvas we as ?@rgiH os 5. MANCHl·.'>I ER J:-\2 I Kosmidis, Denning . Thorax 2015;70:270–277. doi:10.1136/thoraxjnl-2014-206291 Allergic Fungal Airway Disease Phenotypes I[ Asthma AAFS SAFS ABPA-S AAFS-asthma associated with fu ngaIsensitization SAFS-severe asthma with funga l sensitization ABPA-S-seropositive a llergic bronchopulmonary aspergi ll osis AB PA-CB-all ergic bronchopulmonary aspergi ll osis with central bronchiectasis Agarwal R, CurrAlfergy Asthma Rep 2011;11:403 Woolnough K et a l, Curr Opin Pulm Med 2015;21:39 9 Stanford Lucile Packard ~ Children's. Health Children's. Hospital CJ Scanford l MEDICINE Stanford MANCHl·.'>I ER J:-\2 I Aspergi 11 us Sensitisation • Skin testing/specific lgE • Surface hydroph,obins - RodA • 30% of patients with asthma • 13% p.atients with COPD • 65% patients with CF MANCHl·.'>I ER J:-\2 I Alternar1a• ABPA •· .ABPA is an exagg·erated response ofthe imm1une system1 to AspergUlus • Com1pUcatio n of asthm1a and cystic f ibrosis (rarell·y TH2 driven COPD o r no identif ied p1 rior resp1 iratory d isease) • ABPA as a comp1 Ucation of asth ma affects around 2.5% of adullts.
    [Show full text]
  • Obliterative Bronchiolitis, Cryptogenic Organising Pneumonitis and Bronchiolitis Obliterans Organizing Pneumonia: Three Names for Two Different Conditions
    Eur Reaplr J EDITORIAL 1991, 4, 774-775 Obliterative bronchiolitis, cryptogenic organising pneumonitis and bronchiolitis obliterans organizing pneumonia: three names for two different conditions R.M. du Bois, O.M. Geddes Over the last five years, increasing confusion has has been applied to conditions in which airflow obstruc­ developed over the use of the terms "bronchiolitis tion is prominent and in which response to treatment is obliterans" and "bronchiolitis obliterans organizing poor. pneumonia". The confusion stems largely from the common use of the term "bronchiolitis obliterans" or "obliterative bronchiolitis" in the diagnostic labels applied "Cryptogenic organizing pneumonitis" or "bronchi· to two entities which are quite distinct clinically but which otitis obliterans organizing pneumonia" (BOOP) bear certain resemblances histologically. Cryptogenic organizing pneumonitis was first described by DAVISON et al. [7] in 1983. The clinical syndrome ObUterative bronchiolitis consisted of breathlessness, malaise, fever, high erythrocyte sedimentation rate (ESR), pneumonic In 1977, GEODES et al. [1] reported the case histories shadowing on chest radiograph with a restrictive of six patients whose clinical condition was characterized pulmonary function defect and low gas transfer coeffi­ by airways obliteration in association with rheumatoid cient. On histological examination of lung biopsy mate· arthritis. The striking clinical features were of rapidly rial, the typical and distinguishing feature was the progressive breathlessness and the fmding on examination presence of connective tissue within the alveoli, alveolar of a high-pitched mid-inspiratory squeak heard over the ducts and, occasionally, in respiratory bronchioles. This lung fields. Chest radiographs showed hyperinflated lungs connective tissue consisted of "loosely woven fibres of but were otherwise normal.
    [Show full text]
  • Sputum Collection Instructions Step 1 Step 2 Step 3
    Sputum Collection Instructions Sputum is mucus or phlegm coughed up from your lungs (not spit, saliva, or nasopharyngeal discharge). Sputum samples are used to diagnose active tuberculosis (TB) and to monitor the effectiveness of TB treatment. Step 1 • Drink plenty of water the night before collection. Best time of day to collect sputum is when you first wake. • Do not eat, drink or smoke before coughing up sputum from the lungs. • Rinse (do not swallow) the mouth with water before sputum is collected to minimize residual food particles, mouthwash, or oral drugs that might contaminate the specimen. Step 2 • Go away from other people either outside or beside an open window before collecting the specimen. This helps protect other people from TB germs when you cough. • Take the plastic tube with you. The collection tube is very clean. Do not open it until you are ready to use it. Carefully open the plastic tube. Step 3 • Take several deep breaths. • Cough hard from deep inside the chest three times to bring sputum up from your lungs. • Spit the sputum into the tube carefully. Try not to touch the rim of the container. • Repeat until you have 1 – 2 tablespoons of sputum in the tube. • Replace the cap tightly on the plastic tube. • Wash and dry the outside of the tube. • Write date of collection in the proper box on the lab slip. Step 4 • Place the primary specimen container (usually a conical centrifuge tube) in the clear plastic baggie that has the biohazard symbol imprint. • Place the white absorbent sheet in the plastic baggie.
    [Show full text]
  • Perinatal/Neonatal Case Presentation
    Perinatal/Neonatal Case Presentation &&&&&&&&&&&&&& Urinary Tract Infection With Trichomonas vaginalis in a Premature Newborn Infant and the Development of Chronic Lung Disease David J. Hoffman, MD vaginal bleeding with suspected abruption resulted in delivery of Gerard D. Brown, DO the infant by Cesarean section. The Apgar scores were 1, 5, and 9 Frederick H. Wirth, MD at 1, 5, and 10 minutes of life, respectively. Betsy S. Gebert, CRNP After delivery, the infant was managed with mechanical Cathy L. Bailey, MS, CRNP ventilation with pressure support and volume guarantee for Endla K. Anday, MD respiratory distress syndrome. She received exogenous surfactant We report a case of a low-birth-weight infant with an infection of the urinary tract with Trichomonas vaginalis, who later developed cystic chronic lung disease suggestive of Wilson-Mikity syndrome. Although she had mild respiratory distress syndrome at birth, the extent of the chronic lung disease was out of proportion to the initial illness. We speculate that maternal infection with this organism may have resulted in an inflammatory response that led to its development. Journal of Perinatology (2003) 23, 59 – 61 doi:10.1038/sj.jp.7210819 CASE PRESENTATION A 956-g, appropriate-for-gestational-age, African–American female was delivered by Cesarean section following 27 5/7 weeks of gestation in breech presentation after a period of advanced cervical dilatation and uterine contractions. Her mother was a 20-year-old gravida 5, para 2022 woman whose prenatal laboratory data were significant for vaginal colonization with Streptococcus agalactiae, treatment for Chlamydia trachomatis, and a history of cocaine and marijuana usage confirmed by urine toxicology.
    [Show full text]
  • Chest Pain in Pediatrics
    PEDIATRIC CARDIOLOGY 0031-3955/99 $8.00 + .OO CHEST PAIN IN PEDIATRICS Keith C. Kocis, MD, MS Chest pain is an alarming complaint in children, leading an often frightened and concerned family to a pediatrician or emergency room and commonly to a subsequent referral to a pediatric cardiologist. Because of the well-known associ- ation of chest pain with significant cardiovascular disease and sudden death in adult patients, medical personnel commonly share heightened concerns over pediatric patients presenting with chest pain. Although the differential diagnosis of chest pain is exhaustive, chest pain in children is least likely to be cardiac in origin. Organ systems responsible for causing chest pain in children include*: Idiopathic (12%-85%) Musculoskeletal (15%-31%) Pulmonary (12%-21%) Other (4%-21%) Psychiatric (5%-17%) Gastrointestinal (4'/0-7%) Cardiac (4%4%) Furthermore, chest pain in the pediatric population is rareZy associated with life-threatening disease; however, when present, prompt recognition, diagnostic evaluation, and intervention are necessary to prevent an adverse outcome. This article presents a comprehensive list of differential diagnostic possibilities of chest pain in pediatric patients, discusses the common causes in further detail, and outlines a rational diagnostic evaluation and treatment plan. Chest pain, a common complaint of pediatric patients, is often idiopathic in etiology and commonly chronic in nature. In one study,67 chest pain accounted for 6 in 1000 visits to an urban pediatric emergency room. In addition, chest pain is the second most common reason for referral to pediatric cardiologist^.^, 23, 78 Chest pain is found equally in male and female patients, with an average *References 13, 17, 23, 27, 32, 35, 44, 48, 49, 63-67, 74, and 78.
    [Show full text]
  • Bronchitis) 2013 Update
    Care Process Model DECEMBER 2013 DIAGNOSIS AND MANAGEMENT OF Acute Cough (Bronchitis) 2013 update This care process model (CPM) is produced by Intermountain Healthcare’s Lower Respiratory Tract Infection Team, a workgroup of the Primary Care Clinical Program. The CPM provides best-practice recommendations for differential IN THIS UPDATE? diagnosis and management of acute cough and bronchitis. WHAT’S NEW Germ Watch is available at • New data showing an upward trend in unnecessary KEY POINTS intermountainphysician.org use of antibiotics for treatment of acute bronchitis — • Diagnosis of acute bronchitis should be made only after ruling reinforcing our need to do better! out other sources of cough — including pneumonia, asthma, influenza, pertussis, • Updated information on sinusitis, and acute exacerbations of chronic bronchitis (AECB). 1 The algorithm on pages 2 and 3 influenza, and pertussis testing and treatment, guides that evaluation and diagnostic process. Local infection surveillance programs such as with links to more information. Germ Watch can provide up-to-date information about communicable diseases that routinely • Summary of evidence base for symptom affect our communities. relief of acute cough (see ACUTE BRONCHITIS • If acute bronchitis is the diagnosis, antibiotics are TREATMENT RECOMMENDATIONS box inside). Unnecessary Antibiotic Use NOT the answer! Despite ongoing evidence that antibiotics • New and revised provider and patient NOT are needed for acute bronchitis, latest data show that their % of adults with acute bronchitis who received an antibiotic education materials to support physicians in prescription within 3 days of office visit (based on SelectHealth data) use is actually increasing. SelectHealth rates rose from 70% in differential diagnosis and evidence-based treatment 2008 to nearly 75% in 2010 (see graph at right), which mirrors 76 74.87% of acute cough (bronchitis) and related illnesses.
    [Show full text]
  • Bronchitis, Acute Chest Cold/ Bronchiolitis
    SCHOOL HEALTH/ CHILDCARE PROVIDER BRONCHITIS, ACUTE CHEST COLD/ BRONCHIOLITIS Bronchitis and bronchiolitis are respiratory conditions that tend to occur more often in the fall and winter months. When infants and young children experience common respiratory viruses and are exposed to secondhand tobacco smoke, they are at risk of developing bronchiolitis, bronchitis, pneumonia, and middle ear infections. CAUSE Many different viruses, such as respiratory syncytial virus (RSV), parainfluenza, influenza, and adenoviruses; Mycoplasma pneumoniae; and some bacteria. Most of these organisms can cause other illnesses and not all persons exposed to the same organism will develop bronchitis or bronchiolitis. SYMPTOMS Usually starts with a runny nose, fever, and a dry, harsh cough that becomes looser as the illness progresses. Older children may cough up green or yellow sputum. Sore throat can occur in some cases. It may take 1 to 2 weeks for the cough to stop. SPREAD Respiratory viruses and bacteria are spread when an infected person coughs or sneezes tiny droplets into the air, and another person breathes them in. Also can be spread by touching the secretions from the nose and mouth of an infected person or by touching hands, tissues, or other items soiled with these secretions and then touching one’s eyes, nose, or mouth. INCUBATION Depends upon the organism that is causing illness. CONTAGIOUS Until shortly before symptoms begin and for the duration of acute symptoms. PERIOD EXCLUSION Childcare and School: Until fever is gone without the aid of fever reducing medication and the child is well enough to participate in routine activities. DIAGNOSIS Recommend parents/guardians call their health care provider if their child has a high fever, persistent sore throat, or persistent cough.
    [Show full text]
  • SAR156597 in Idiopathic Pulmonary Fibrosis: a Phase 2, Placebo-Controlled Study (DRI11772)
    ERJ Express. Published on October 18, 2018 as doi: 10.1183/13993003.01130-2018 Early View Original article SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772) Ganesh Raghu, Luca Richeldi, Bruno Crestani, Peter Wung, Raphael Bejuit, Corinne Esperet, Christian Antoni, Christina Soubrane Please cite this article as: Raghu G, Richeldi L, Crestani B, et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772). Eur Respir J 2018; in press (https://doi.org/10.1183/13993003.01130-2018). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2018 Copyright 2018 by the European Respiratory Society. SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772) Ganesh Raghu1, Luca Richeldi2, Bruno Crestani3, Peter Wung4, Raphael Bejuit5, Corinne Esperet5, Christian Antoni5 and Christina Soubrane5 Affiliations: 1Center for Interstitial Lung Diseases, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington Medical Center, Seattle, WA, USA. 2Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolicà del Sacro Cuore, Roma, Italy. 3APHP, Hôpital Bichat, Service de Pneumologie A, Centre de Référence Constitutif des Maladies Pulmonaires Rares, DHU FIRE, Paris, France; Université Paris Diderot, Sorbonne Paris Cité; INSERM Unité 1152, Paris, France. 4Medical Operations, Sanofi R&D, Bridgewater, NJ, USA. 5Immunology and Inflammation Therapeutic Area, Sanofi R&D, Paris, France.
    [Show full text]